Pharma companies in the U.S.
Pharmaceutical sales revenues in the United States have accounted for nearly half of the global total in recent years. Five of the 10 leading pharmaceutical companies worldwide were from the U.S. in 2021. Pfizer is the new number one U.S. company based on prescription drug revenues worldwide, heavily boosted by its COVID-19 vaccine Comirnaty. AbbVie is another U.S. company that has made a big impression around the world, with the pharmaceutical segment of its operations generating a record 55 billion U.S. dollars in 2021, driven especially by its longstanding top-seller Humira.The impact of COVID-19 on R&D
The U.S. pharmaceutical industry has made great strides over the past few decades due to a greater focus on research and development (R&D). Pharma companies spend over 21 percent of their revenues on R&D, and this sizeable investment is wasted if a medication does not receive regulatory approval. The R&D expenditure of the U.S. pharmaceutical industry totaled some 102 billion U.S. dollars in 2021. It is very likely that this figure will significantly increase in the years to come due to the costs associated with developing safe and effective COVID-19 treatments and vaccines.The high costs of prescription drugs
Prescription drug prices in the United States are among the highest in the world, and recent years have been especially profitable for the American pharmaceutical industry. The blockbuster drug Humira, which is produced by AbbVie, generated approximately 17 billion U.S. dollars from sales in the United States in 2021. Overall spending on medicines in the U.S. has by far exceeded half a trillion billion U.S. dollars, even when factoring discounts and rebates that help to lower costs. Soaring prices and increasing premiums are sources of constant debate, and more than two-thirds of Americans believe drug prices are usually much higher than what consumers should be paying.
